Probiotic Bacteria in Prevention of the Metabolic Syndrome

NCT02288572 | Completed Phase 2

• 1 other identifier: MGPS001
• Study Type: interventional
• Target: 16
• Locations: 0 countries
• Sites: N/A

Brief Summary

The metabolic syndrome is increasing worldwide, including developing countries. The metabolic syndrome is composed of clinical expressed symptoms as central obesity, high blood pressure, raised fasting plasma glucose or diagnosed diabetes, low HDL, and raised serum triglycerides. All those components together or independently contribute to the development of cardiovascular diseases, which are the leading cause of death in the modern world. The results from previous studies have shown that probiotic bacteria have an influence on health improvement, and can exert positive effects on diseases as diabetes, high blood pressure, dyslipidemia and low-grade inflammation, which are all components of the metabolic syndrome. The objectives of this study were to investigate which of probiotic strains Lactobacillus plantarum PCS 20, Lactobacillus plantarum PCS 26 in Lactobacillus rhamnosus GG exert positive effects in the cascade of molecular reactions at the level of small intestines, at remodeling of monocytes/macrophages and adipocytes in human cell model of non-cancerous origin, and to provide scientific explanation of mechanisms of possible multi-leveled activity of selected probiotic strains in patients with metabolic syndrome. For this purpose, the investigators divided this research into two parts. The first part consisted of pre-clinical in-vitro laboratory study. It examined the mechanisms of actions of probiotic cultures with the use of functional cell models of non-cancerous origin, more specifically, with the use of cell lines of human intestinal epithelium, human monocytes/macrophages and human visceral preadipocytes. In in-vitro laboratory study, the investigators demonstrated that probiotic strain Lactobacillus plantarum PCS 26 exerts positive effects, which could help to relieve the particular components of the syndrome in the host with metabolic syndrome. The second part of the research consisted of prospective, double-blind and placebo-controlled in-vivo pilot clinical study, which included 16 volunteers with the metabolic syndrome. Results have shown that probiotic strain Lactobacillus plantarum PCS 26 exerts positive effects on reduction of waist circumference, on lowering of serum cholesterol concentration, and on maintenance of serum adiponectin levels. Those effects together can contribute to the alleviation of the metabolic syndrome, especially in terms of clinical manifestation and risks in relation to cardiovascular diseases.

Conditions

Metabolic Syndrome X

Keywords

metabolic syndrome X; obesity; insulin resistance; dyslipidemia; probiotic bacteria

Outcome Measures

Primary Outcomes (1)

• Serum lipids concentrations after daily consumption of dietary supplement in patients with the metabolic syndrome

  Serum total cholesterol, triglycerides, LDL and HDL concentrations

  3 months

Secondary Outcomes (1)

• Measures of body composition after daily consumption of dietary supplement in patients with the metabolic syndrome

  3 months

Study Arms (2)

Lactobacillus plantarum PCS 26

ACTIVE COMPARATOR

Dosage: 1.000.000.000 Colony Forming Units (CFU) per day in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey

Dietary Supplement: Lactobacillus plantarum PCS 26

Placebo

PLACEBO COMPARATOR

Only vehicle components in powdery form for 3 months Vehicle: 70 % glucose, 15 % powder milk, 15 % whey

Dietary Supplement: Placebo

Interventions

Lactobacillus plantarum PCS 26 DIETARY_SUPPLEMENT

Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.

Lactobacillus plantarum PCS 26

Placebo DIETARY_SUPPLEMENT

Taking dietary supplement on a daily basis for 3 months.

Placebo

Eligibility Criteria

• Age: 21 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• visceral obesity and at least two of other components: raised fasting serum glucose or known diabetes type 2; raised fasting serum triglycerides; raised fasting serum cholesterol; raised fasting serum LDL and low fasting serum HDL; high blood pressure, more than 130/85 mmHg.

You may not qualify if:

• planned invasive procedure or surgery (whole body);
• planned surgery in mouth cavity;
• weakened immune system or taking immunosuppressives;
• diagnosed inflammatory bowel disease;
• known or diagnosed lactose intolerance.

Sponsors & Collaborators

• University Maribor: lead
• Slovenian Research Agency: collaborator

MeSH Terms

Conditions

Metabolic Syndrome; Obesity; Insulin Resistance; Dyslipidemias

Condition Hierarchy (Ancestors)

Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Lipid Metabolism Disorders

Study Officials

• Pavel Skok, DSc, MD

  University Medical Centre Maribor

  STUDY CHAIR

• Mario Gorenjak, DSc, MBioinf, BHSc

  Faculty of Medicine, University of Maribor

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Biomedical field scientist

Study Record Dates

• First Submitted: November 2, 2014
• First Posted: November 11, 2014
• Study Start: May 1, 2013
• Primary Completion: March 1, 2014
• Study Completion: May 1, 2014
• Last Updated: November 11, 2014

Record last verified: 2014-11